Integrated Computational Approaches for Drug Design Targeting Cruzipain

Int J Mol Sci. 2024 Mar 27;25(7):3747. doi: 10.3390/ijms25073747.

Abstract

Cruzipain inhibitors are required after medications to treat Chagas disease because of the need for safer, more effective treatments. Trypanosoma cruzi is the source of cruzipain, a crucial cysteine protease that has driven interest in using computational methods to create more effective inhibitors. We employed a 3D-QSAR model, using a dataset of 36 known inhibitors, and a pharmacophore model to identify potential inhibitors for cruzipain. We also built a deep learning model using the Deep purpose library, trained on 204 active compounds, and validated it with a specific test set. During a comprehensive screening of the Drug Bank database of 8533 molecules, pharmacophore and deep learning models identified 1012 and 340 drug-like molecules, respectively. These molecules were further evaluated through molecular docking, followed by induced-fit docking. Ultimately, molecular dynamics simulation was performed for the final potent inhibitors that exhibited strong binding interactions. These results present four novel cruzipain inhibitors that can inhibit the cruzipain protein of T. cruzi.

Keywords: MD simulation; QSAR; deep learning model; molecular docking; pharmacophore model.

MeSH terms

  • Chagas Disease* / drug therapy
  • Cysteine Endopeptidases*
  • Drug Design
  • Humans
  • Molecular Docking Simulation
  • Protozoan Proteins

Substances

  • cruzipain
  • Cysteine Endopeptidases
  • Protozoan Proteins

Grants and funding

This work was supported by the Jeonju University research year to Prof./Dr. J-.S.Lee in 2022 and funded from the Ministry of Science and ICT (Korea government) in 2023 (2023-JB-RD-0103) (Jeonbuk Innopolish, Research Company Seed Fund Project) to GSCRO.